The combined company will be headquartered in Dublin, Ireland, where Mallinckrodt’s HQ is based, following the close of the merger agreement. Mallinckrodt and Endo said the location of the ...

Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments. The agreement will give ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.

After cash consideration, Mallinckrodt shareholders will own 50.1% of the combined entity on a pro forma basis for an implied pro forma enterprise value of $6.7 billion. See Also: Endo Weighing ...

All told, the drugmakers project that the combined company will generate $3.6 billion in 2025 revenue, plus earnings of $1.2 billion. The new entity, which will be based out of Mallinckrodt’s ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said. The drugmakers, which both emerged ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

DUBLIN and MALVERN, Pa. - Mallinckrodt plc and Endo International plc announced a definitive merger agreement in a stock and cash transaction. The deal is set to create a global pharmaceuticals ...

According to the 13 March announcement, the merger will create a “larger, more diversified entity”, with Mallinckrodt shareholders holding a 50.1% stake and Endo shareholders receiving 49.9% ...